QuantuMDx Group Ltd
QuantuMDx is a progressive medical technology company passionate about empowering the world to control disease and reduce suffering. They focus on creating rapid multiplex PCR solutions and microarray technologies for the Point of Care, aiming to make transformative diagnostic solutions accessible to everyone for earlier disease detection and treatment. Their innovations include multiplex diagnostic platforms and assays that address infectious diseases, antimicrobial resistance, cancer, prenatal screening, and pharmacogenomics.
Industries
Nr. of Employees
medium (51-250)
QuantuMDx Group Ltd
Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom, Europe
Products
Point-of-need multiplex PCR platform
Compact, rapid sample-to-answer multiplex PCR instrument designed to run single-use microfluidic cassettes and deliver results in approximately 30–35 minutes for use near the point of care.
Respiratory multiplex PCR assay (SARS-CoV-2 / influenza A/B / RSV)
A cassette-compatible multiplex PCR assay configured to detect and differentiate common respiratory viruses within a single run with ~34–35 minute runtime; includes workflows that use throat sampling for some use cases.
Laboratory RT-qPCR host-response mRNA assay (6-gene panel)
Laboratory-based multiplex one-step RT-qPCR assay amplifying a six-gene host mRNA signature from extracted blood RNA for research use, with planned pathway for point-of-need adaptation.
Microfluidic sample clean-up and concentration prototype
Prototype lab-on-chip technology for sample clean-up and pathogen/cell concentration intended to support downstream molecular assays.
Point-of-need multiplex PCR platform
Compact, rapid sample-to-answer multiplex PCR instrument designed to run single-use microfluidic cassettes and deliver results in approximately 30–35 minutes for use near the point of care.
Respiratory multiplex PCR assay (SARS-CoV-2 / influenza A/B / RSV)
A cassette-compatible multiplex PCR assay configured to detect and differentiate common respiratory viruses within a single run with ~34–35 minute runtime; includes workflows that use throat sampling for some use cases.
Laboratory RT-qPCR host-response mRNA assay (6-gene panel)
Laboratory-based multiplex one-step RT-qPCR assay amplifying a six-gene host mRNA signature from extracted blood RNA for research use, with planned pathway for point-of-need adaptation.
Microfluidic sample clean-up and concentration prototype
Prototype lab-on-chip technology for sample clean-up and pathogen/cell concentration intended to support downstream molecular assays.
Services
Collaborative future assay development
Partnerships to co-develop new multiplex molecular assays for deployment on a point-of-need platform, including early evaluation and validation support.
LIS / IT integration support
Software and workflow support to configure secure automatic transfer of test results to laboratory information systems using HL7 CDA standards.
Distribution and customer support
Documentation, training materials and distributor support to enable product distribution and field deployment.
Collaborative future assay development
Partnerships to co-develop new multiplex molecular assays for deployment on a point-of-need platform, including early evaluation and validation support.
LIS / IT integration support
Software and workflow support to configure secure automatic transfer of test results to laboratory information systems using HL7 CDA standards.
Distribution and customer support
Documentation, training materials and distributor support to enable product distribution and field deployment.
Expertise Areas
- Point-of-care molecular diagnostics
- Multiplex PCR assay development
- Host-response (mRNA) biomarker assays
- Microarray-based high-plex screening and analysis
Key Technologies
- Multiplex PCR
- One-step RT-qPCR
- Cassette-based microfluidic sample-to-answer systems
- Host mRNA signature detection